Results 91 to 100 of about 181,580 (299)

Treat-and-extend therapy using intravitreal aflibercept for neovascular age-related macular degeneration: 2-year real-world practice data from Slovenia

open access: yesBMC Ophthalmology, 2018
Background To assess visual outcomes over 24 months in patients with neovascular age-related macular degeneration (nAMD) who initiated intravitreal aflibercept therapy under a treat-and-extend (TE) regimen in real-world settings.
Polona Jaki Mekjavić   +3 more
doaj   +1 more source

A Cre‐dependent lentiviral vector for neuron subtype‐specific expression of large proteins

open access: yesFEBS Letters, EarlyView.
We designed a versatile and modular lentivector comprising a Cre‐dependent switch and self‐cleaving 2A peptide and tested it for co‐expression of GFP and a 2.8 kb gene of interest (GOI) in mouse cortical parvalbumin (PV+) interneurons and midbrain dopamine (TH+) neurons.
Weixuan Xue   +6 more
wiley   +1 more source

Anatomical and functional response after conversion to aflibercept using the treat-and-extend regimen protocol in bevacizumab treatment-resistant wet age-related macular degeneration

open access: yesClinical Ophthalmology, 2018
Claudia Taipale,1,2 Ilkka Laine,1,3 Raimo Tuuminen1,3 1Helsinki Retina Research Group, Medicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland; 2Department of Ophthalmology, Helsinki University Hospital, Helsinki, Finland; 3Department of
Taipale C, Laine I, Tuuminen R
doaj  

By dawn or dusk—how circadian timing rewrites bacterial infection outcomes

open access: yesFEBS Letters, EarlyView.
The circadian clock shapes immune function, yet its influence on infection outcomes is only beginning to be understood. This review highlights how circadian timing alters host responses to the bacterial pathogens Salmonella enterica, Listeria monocytogenes, and Streptococcus pneumoniae revealing that the effectiveness of immune defense depends not only
Devons Mo   +2 more
wiley   +1 more source

Five-year outcomes of intravitreal drug therapy for neovascular age-related macular degeneration in eyes with baseline vision 20/60 or better

open access: yesClinical Ophthalmology, 2019
Arshad M Khanani,1 Greggory M Gahn,2 Micaela M Koci,2 Jonathan M Dang,2 Sandra M Brown,3 Lauren F Hill4 1Sierra Eye Associates, Reno, NV, USA; 2School of Medicine, University of Nevada, Reno, NV, USA; 3Cabarrus Eye Center, Concord, NC, USA; 4Hill  ...
Khanani AM   +5 more
doaj  

Comparative study on the efficacy of different aflibercept regimens in the treatment of macular edema secondary to branch retinal vein occlusion

open access: yesFrontiers in Medicine
ObjectivesTo compare the efficacy of intravitreal injection of aflibercept between the treat-and-extend (TAE) and pro re nata (PRN, as needed) regimens in the treatment of macular edema secondary to branch retinal vein occlusion, to determine the best ...
Xing Du   +6 more
doaj   +1 more source

Treat and extend regimen with aflibercept for choroidal neovascularization in angioid streaks [PDF]

open access: yesEye, 2016
Treat and extend regimen with aflibercept for choroidal neovascularization in angioid ...
openaire   +1 more source

Hematopoietic (stem) cells—The elixir of life?

open access: yesFEBS Letters, EarlyView.
The aging of HSCs (hematopoietic stem cells) and the blood system leads to the decline of other organs. Rejuvenating aged HSCs improves the function of the blood system, slowing the aging of the heart, kidney, brain, and liver, and the occurrence of age‐related diseases.
Emilie L. Cerezo   +4 more
wiley   +1 more source

Phosphatidylinositol 4‐kinase as a target of pathogens—friend or foe?

open access: yesFEBS Letters, EarlyView.
This graphical summary illustrates the roles of phosphatidylinositol 4‐kinases (PI4Ks). PI4Ks regulate key cellular processes and can be hijacked by pathogens, such as viruses, bacteria and parasites, to support their intracellular replication. Their dual role as essential host enzymes and pathogen cofactors makes them promising drug targets.
Ana C. Mendes   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy